HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Significant responses to platinum-based chemotherapy in renal medullary carcinoma.

Abstract
Most patients with renal medullary carcinoma (RMC) have advanced disease at presentation and rarely respond to radiation or chemotherapy. We describe two adolescents with metastatic disease who had significant responses to cisplatin or carboplatin in combination with gemcitabine and paclitaxel.
AuthorsJohn J Strouse, Melissa Spevak, A Kyle Mack, Robert J Arceci, Donald Small, David M Loeb
JournalPediatric blood & cancer (Pediatr Blood Cancer) Vol. 44 Issue 4 Pg. 407-11 (Apr 2005) ISSN: 1545-5009 [Print] United States
PMID15602719 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Deoxycytidine
  • Carboplatin
  • Paclitaxel
  • Cisplatin
  • Gemcitabine
Topics
  • Adolescent
  • Black or African American
  • Anemia, Sickle Cell (complications)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Carboplatin (administration & dosage, therapeutic use)
  • Carcinoma, Renal Cell (complications, drug therapy)
  • Cisplatin (administration & dosage, therapeutic use)
  • Deoxycytidine (administration & dosage, analogs & derivatives)
  • Female
  • Humans
  • Kidney Medulla
  • Kidney Neoplasms (complications, drug therapy)
  • Male
  • Paclitaxel (administration & dosage)
  • Treatment Outcome
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: